USA and India continue disagreement on IP protection

17 March 2014
gipc-big

India’s record to uphold intellectual property rights is anything but solid, a major US business group has pointed out, even as the Indian government stands its ground maintaining that its laws are in consonance with the World Trade Organization led agreements, writes The Pharma Letter’s India correspondent.

Though the US Chamber of Commerce's Global Intellectual Property Center (GIPC) recently noted that India has the worst record on issues such as respect of patents, copyrights and international treaties, underlined by an ongoing controversy over pharmaceuticals, Indian drugmakers have countered that the World Health Organization has endorsed India's patent laws, and that no country has challenged these laws at the WTO.

In GIPC's International IP Index report, India has been ranked at the bottom of the list of 30 countries - below Ukraine, the only country currently designated as a Priority Foreign Country by the US government.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical